Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02345226 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Adults
A Phase 3 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 881
- Enrollment target
NCT02345226 is a Phase 3 study that has completed, run by Gilead Sciences. The registered enrollment target is 881 participants.
The verdict
NCT02345226, a Phase 3 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 881 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the non-inferiority of switching to emtricitabine/rilpivirine/tenofovir alafenamide (FTC/RPV/TAF) fixed dose combination (FDC) as compared to continuing the non-nucleoside reverse transcriptase inhibitor (NNRTI) regimen of efavirenz /FTC/tenofovir disoproxil fumarate (EFV/FTC/TDF) FDC in virologically-suppressed HIV-1 infected participants.
Interventions
- DRUG EFV/FTC/TDF
- DRUG FTC/RPV/TAF
- DRUG EFV/FTC/TDF Placebo
- DRUG FTC/RPV/TAF Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 881 participants |
| Start Date | 2015-01-26 |
| Est. Completion | 2019-01-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02345226
The ClinicalTrials.gov registry entry for NCT02345226 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 881 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which EFV/FTC/TDF is the first listed.
NCT02345226 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02345226 about?
NCT02345226 is a clinical study titled "Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Adults". The primary objective of this study is to evaluate the non-inferiority of switching to emtricitabine/rilpivirine/tenofovir alafenamide (FTC/RPV/TAF) fixed dose combination (FDC) as compared to continuing the non-nucleoside reverse transcriptase inhibitor (NNRTI) regimen of efavirenz /FTC/tenofovir d...
What is the current status of trial NCT02345226?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 881 participants. The study started on 2015-01-26. Estimated completion is 2019-01-02.
What interventions are being tested in trial NCT02345226?
The interventions under investigation include: EFV/FTC/TDF (DRUG), FTC/RPV/TAF (DRUG), EFV/FTC/TDF Placebo (DRUG), FTC/RPV/TAF Placebo (DRUG).
Who is sponsoring clinical trial NCT02345226?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.